Shanghai Kaisai Biotechnology Co., LTD. (hereinafter referred to as "Kaisai Bio") is a company based on synthetic biology and other disciplines, the use of biological manufacturing technology, A high-tech enterprise engaged in the research and development, production and sales of new bio-based materials.

now realize commercial production of the products are mainly gather focal The industrial chain of polyamide is bio-based polyamide and raw materials that can be used for the production of bio-based polyamide, including DC12 (lauric acid), DC13 (Brazilian acid) and other bio-based long chain dibasic acid series products and bio-based glutenediamine.

01, listing and raising projects

On August 12, 2020, Kaisai Biologics (stock code: 688065) officially landed on the Science and Technology Innovation Board of Shanghai Stock Exchange; And raised funds for investment in the following projects: Kaisai (Jinxiang) Biological Materials Co., LTD. 40,000 tons/year biological method sebacic acid project, Kaisai (Wusu) Biotechnology Co., LTD. Annual output of 30,000 tons of long chain dibasic acid and 20,000 tons of long chain polyamide project, supplement working capital.

1, Kaisai (Jinxiang) Biomaterials Co., LTD. 40,000 tons/year biological Sebacic acid project

This project is implemented by Jinxiang Kaisai, to build a new capacity of 40,000 tons of biological sebacic acid, to develop the market of biological sebacic acid. The project construction period of 14 months, the planned total investment of 171,1020 million yuan.

2, Bio-based polyamide Engineering technology Research center

This project is implemented by Jinxiang Kaisai, and intends to become one of the main research and development bases of bio-based polyamide engineering technology of the company. The construction period of the project is 12 months, with a planned total investment of 20,789.00 yuan.

3, Kaisai (Usu) Biotechnology Co., Ltd. annual output of 30,000 tons of long chain dibasic acid and 20,000 tons of long chain polyamide project

This project is implemented by Usu Technology, and will achieve an annual output of 30,000 tons of long chain dibasic acid and 20,000 tons of biological long chain polyamide products. The construction period of the project is 38 months, with a planned total investment of 148,71890 million yuan.

4. Supplementary working capital

The Company intends to use the raised funds of 2 billion yuan to supplement the working capital, in order to optimize the financial structure, reduce the liquidity risk, and meet the fund needs of the company's subsequent production and operation development.

02, financial data

2017-2019, cathay biotechnology major accounting data and financial indicators are as follows:

2017-2019, cathay life advocate business wu income according to the product categories are as follows:

2017-2019, cathay biological and advocate business wu income situation shown in the table below:

03, r&d

in 2017, 2018 and 2019, the company research and development costs of 6456.02 ten thousand yuan respectively, 8639.38 ten thousand yuan and ten thousand yuan 9015.95, Accounted for 4.74%, 4.92% and 4.71% of the operating income, respectively. The specific composition is as follows:

The company has established a multi-disciplinary professional R & D team, with rich experience in molecular biology, chemistry, polymerization, material application and other aspects. As of December 31, 2019, the number of core technical personnel and R & D personnel of the company is as follows:

04, production statistics

according to public information, cathay biological existing biological method of long chain dibasic acid production capacity of 75000 tons/year, At present, the company 100,000 tons/year bio-based polyamide, 50,000 tons/year bio-based glutenediamine and 40,000 tons/year bio-based sebacic acid are in the process of industrialization, and 20,000 tons/year bio-based long chain polyamide is in the laboratory research and development stage. In addition, the company will realize the industrialization of 900,000 tons/year of bio-based polyamide and 500,000 tons/year of bio-based pentadiamine in Shanxi base in the future.

5, the main customer